Severe tumefactive rebound of multiple sclerosis following fingolimod cessation
نویسندگان
چکیده
منابع مشابه
Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
Introduction: Multiple sclerosis (MS) is a lifelong disease of the brain and spinal cord. Fingolimod is an oral drug which modulates the S1P receptor and is used for relapsing remitting form of MS and can causes rebound activity if it is ceased even in a short period of washout time. Case Report: Here, we introduce a young girl, a known case of MS, who developed revers...
متن کاملTumefactive multiple sclerosis plaque.
W e present a case of a large solitary demyelinating plaque in the brain masquerading as tumour. A 34 year old healthy woman presented with sudden onset of left hemiparesis. Subsequent MRI of the brain showed a single large 2.5 cm right sided enhancing lesion within the white matter of the parietal lobe (fig 1). The lesion appeared to originate from the corpus callosum. Diffusion weighted and g...
متن کاملTumefactive Multiple Sclerosis in Taiwan
BACKGROUND Multiple sclerosis (MS) is less common in Asia, including Taiwan, and some characteristics of MS in Asians differ from those of Caucasians. Tumefactive brain lesion is even rarer in MS patients. OBJECTIVE To review patients with tumefactive MS and compare them with those in other studies investigating tumefactive demyelinating lesions and our Taiwanese typical MS patients. METHOD...
متن کاملFingolimod and multiple sclerosis
Neurology 2012;79:1942–1943 Unexpected consequences arise from our incomplete knowledge of the immune system. Who, for example, would have predicted that natalizumab, a monoclonal antibody targeting 4 integrin on leukocytes, would dramatically increase the risk of developing progressive multifocal leukoencephalopathy without causing notable immunosuppression? Thus, any new immunomodulatory ther...
متن کاملAn observational study of alemtuzumab following fingolimod for multiple sclerosis
OBJECTIVE To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab. METHODS Patients with relapsing MS treated sequentially with fingolimod then alemtuzumab who experienced significant subsequent disease activity were identified by personal commu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ Case Reports
سال: 2016
ISSN: 1757-790X
DOI: 10.1136/bcr-2016-215596